News

Treatment with the investigational drug efzofitimod — given by infusion once every four weeks — significantly improved general health and lung-related quality of life in adults with pulmonary sarcoidosis while also significantly easing fatigue and numerically reducing the use of oral corticosteroids. Lung function was also preserved among…

The Foundation for Sarcoidosis Research (FSR) has added nine institutions to its Global Sarcoidosis Clinic Alliance, bringing the international network to 55 member clinics and hospitals working to advance sarcoidosis research and improve patient care. The new members include eight institutions joining the alliance for the first time,…

Levels of certain proteins carried by extracellular vesicles (EVs), tiny cargo-filled sacs released by cells, may help predict whether people with pulmonary sarcoidosis respond to standard treatment with prednisone or methotrexate, a study suggests. Higher levels of three EV-carried proteins involved in immune responses were associated with a better…

Outcomes among more than 1,800 people newly diagnosed with cardiac sarcoidosis differed by diagnostic features, including heart tissue sampling to confirm the disease and whether it also affected other organs, a large real-world study using registry data found. The group of patients diagnosed without a heart biopsy and with…

A study examining patients’ blood and lymph nodes at the time of sarcoidosis diagnosis and before treatment found signs of inflammation but no detectable microorganisms, challenging the long-held hypothesis that infectious microorganisms may cause sarcoidosis. “Our findings demonstrate that the inflammatory response…

Over the coming months, Atyr Pharma will be working toward the launch of a global clinical trial testing its therapy candidate efzofitimod in people with moderate to severe pulmonary sarcoidosis and restrictive lung disease, which together make it difficult for the lungs to fully expand, hampering breathing. The…

People with sarcoidosis but no documented liver involvement have a nearly threefold higher risk of developing permanent liver scarring (cirrhosis) than those without the inflammatory disease, according to a large, population-based study from Israel. The risk was particularly elevated among patients whose sarcoidosis affected multiple organs. Still, the absolute…

Heart inflammation that persists after initial treatment may signal disease relapse in people with cardiac sarcoidosis, and advanced imaging could help identify patients who warrant monitoring, a study found. Most relapses occurred in areas of the heart that had previously been affected, and more than half of patients with…

Three genes not previously established as major genetic contributors to sarcoidosis — RFTN2, FAM117B, and RNF215 — may influence a person’s susceptibility to the inflammatory disease, according to a large genetic analysis. Using genetic information from more than 5,000 people living with sarcoidosis and nearly 500,000 without the disease,…

Sarcoidosis patients, caregivers, healthcare professionals, and researchers in the Mid-Atlantic will have the opportunity to come together to strengthen sarcoidosis care and build support networks at a free summit on Sept. 26 in Philadelphia. The Foundation for Sarcoidosis Research (FSR) is hosting the regional summit to allow patients…